Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes ...

Danish drugmaker Novo Nordisk (NVO) reported fourth quarter ... Wegovy for weight loss and Ozempic for diabetes, were key to its earnings beat. Combined, they brought in $24.9 billion for the ...

We speak to him about the company’s drive to tackle the complications of type 2 diabetes ... for us at Novo Nordisk. Digital health can support patients and health care professionals in several ...

Digital health company Liva Healthcare has acquired UK-based Momenta, a provider of digital, virtual, and in-person healthy ...

Novo Nordisk has achieved another blockbuster financial year as the group cheered intense global demand for its obesity and diabetes drugs. The Danish pharmaceutical giant reported turnover from ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t ...

The settlement filed in Newark, N.J. federal court comes after similar settlements with Eli Lilly and Sanofi last year. It ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

With sales of Novo Nordisk’s obesity blockbuster Wegovy ... While Novo’s type 2 diabetes GLP-1 Ozempic has largely stolen the show in recent years, obesity med Wegovy—which utilizes the ...

Novo Nordisk A/S is prepared for potential tariffs ... The US is a key market for Novo’s top products, including Ozempic for diabetes and the Wegovy weight-loss therapy.